Revenue grew 14.43% to RMB 31.60 billion and net profit rose 1.58% to RMB 3.42 billion, driven by strong CHC and prescription drug segments, major R&D investment, and the acquisition of Tian Shi Li. Dividend payout ratio reached 50.59% for 2025.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.